Trial Profile
An Open-Label, Single-Dose Study to Investigate the Influence of Renal Insufficiency on the Pharmacokinetics of MK-7264
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Gefapixant (Primary)
- Indications Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 03 Jun 2022 Results published in the Journal of Clinical Pharmacology
- 19 Sep 2017 Status changed from active, no longer recruiting to completed.
- 04 Sep 2017 Status changed from recruiting to active, no longer recruiting.